AstraZeneca CEO Sees Over $20B Potential From 2027 Drug Trial Readouts – AZN Stock Eyes Breakout After Q3 Earnings Beat

AstraZeneca reported a 7% increase in Q3 revenue to $16.21 billion, beating Wall Street estimates of about $16 billion, according to Fiscal.ai.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stocktwits.com)